Olivier Bohuon Joins Pierre Fabre

Castres, France, July 2, 2010 (ots/PRNewswire) - Olivier Bohuon will be
replacing Jean-Pierre Garnier as Chief Executive Officer at Pierre
Fabre Group starting September 1, 2010.

Until now, Olivier Bohuon, 51, was Executive Vice-President of
the Abbott Corporation and President of its pharmaceutical division.
As such, he ran the group's entire pharmaceutical activities from
Chicago ($22 billion in sales). In 2003, he was named the group's
President for European operations and later became President of
Abbott International.

Prior to that, before beginning his career at Roussel Uclaf in
Morocco (and later in the Middle East), Olivier Bohuon was the
Marketing Director and then the Operations Director of Glaxo France
(1991-1995), CEO and then President of SmithKline Beecham
Laboratories (1995-2001), and Director of GlaxoSmithKline's
Commercial Operations, Europe (2001-2003).

Olivier Bohuon holds a Doctor of Pharmacy as well as an HEC MBA.

He is a member of the National Pharmacy Academy and the Academy
of Technologies and is a knight of the Légion d'Honneur.

After an international career, at the end of which he was
entrusted with the highest operational responsibilities within the
pharmaceutical sector, Olivier Bohuon chose to return to France to
pursue his career there.

In addition to his duties as the group's CEO, he will also act as
President of Pierre Fabre Medicament.

When his arrival at Pierre Fabre was announced, Olivier BOHUON
stated, "I will head the group in close collaboration with his
chairman and founder and we will jointly paving the future; my action
will be registered in the long run."

About the Pierre Fabre group:

The Pierre Fabre Group, the second largest independent French
pharmaceutical company and leader in the field of in-pharmacy
dermo-cosmetics, employs about 10,000 people worldwide, including
1,400 R&D staff, and generates a sales turnover of EUR1.8 billion.

In 2009, Pierre Fabre Medicament dedicated 28% of its annual
turnover to R&D in four priority therapeutic areas in public health:
oncology, central nervous system, dermatology,
cardio-vascular/metabolism.

To learn more about Pierre Fabre, please refer to
http://www.pierre-fabre.com.

ots Originaltext: Groupe Pierre Fabre
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Press Contact : Djamila
Hazene-Kedjem,djamila.hazene.kedjem@pierre-fabre.com ,
+33(0)1-49-10-81-12 /+33(6)-89-45-87-95